Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccinex Inc (NQ: VCNX )

6.440 -0.240 (-3.59%)
Streaming Delayed Price Updated: 12:56 PM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,956
Open 6.850
Bid (Size) 4.500 (1)
Ask (Size) 6.850 (1)
Prev. Close 6.680
Today's Range 6.440 - 6.850
52wk Range 0.5115 - 10.10
Shares Outstanding 65,941,086
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga

Performance

YTD
+754.34%
+754.34%
1 Month
-9.42%
-9.42%
3 Month
-3.77%
-3.77%
6 Month
+754.34%
+754.34%
1 Year
+21.42%
+21.42%

More News

Read More
VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024
Via InvestorPlace
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
Via InvestorPlace
Why Vaccinex (VCNX) Stock Is Trading Lower
Via Benzinga
Why Vaccinex (VCNX) Stock Is Popping Off
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex, Inc. Announces Reverse Stock Split
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
From Vaccinex, Inc.
Via GlobeNewswire
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
From Vaccinex, Inc.
Via GlobeNewswire
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.